JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

• Market Cap: ₹768.72M
• Dividend Yield: N/A
• Average Volume (3M): 16.78K
• Price to Earnings (P/E): 27.3
• Beta (1Y): 0.95
• Revenue Growth: 16.77%
• EPS Growth: 34.47%
• Country: IN
• Employees: 250
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.09
• Shares Outstanding: 85,603,966
• 10 Day Avg. Volume: 16,348
• 30 Day Avg. Volume: 16,781
• PEG Ratio: -0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -6.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹9.50 ▲(1.71% Upside)
• Action: Reiterated Date: 01/23/26
• Date: Action: Reiterated 01/23/26

The score is held back primarily by weak financial performance (multi-year revenue decline, ongoing losses, and negative free cash flow), partially offset by a strong equity-heavy balance sheet with low leverage. Technical indicators are moderately positive in the short term, but valuation is constrained by negative earnings and no dividend yield data.

Positive Factors

Strong equity-heavy balance sheet

An equity ratio of 85.83% and negligible debt (D/E 0.037) provide durable financial resilience. Low leverage preserves borrowing capacity, reduces solvency risk, and gives management flexibility to fund working capital or capex through equity or internal resources during multi-quarter recoveries in contract manufacturing volumes.

Contract manufacturing business model

A core contract-manufacturing and private-label model creates recurring, order-driven revenue and long-term supply relationships. This structural positioning reduces marketing burden, supports predictable plant utilization when customers commit to supply agreements, and leverages scale across FMCG customers over months to years.

Improved gross margin

Gross margin improvement to 33.66% in 2025 signals better cost management or product mix at the factory level. Sustained higher gross margins provide a buffer against raw-material inflation, improve chances of turning EBITDA positive as volumes recover, and increase operational leverage for long-term profitability restoration.

Negative Factors

Multi-year revenue decline

A material revenue decline over 2020–2025 is a structural alarm: lower volumes reduce fixed-cost absorption at manufacturing plants, weaken negotiating power with suppliers and customers, and can permanently impair scale economics. Recovery typically requires sustained order wins or new customer contracts over many quarters.

Persistent unprofitability

Sustained losses since 2021 and a -21.47% net margin in 2025 erode equity and limit reinvestment. Negative operating profitability constrains capacity to self-fund growth or working capital, increases dependence on external financing, and makes it harder to restore investor and customer confidence over the medium term.

Negative free cash flow and poor cash conversion

Negative free cash flow and deterioration in 2025 indicate weak cash conversion and liquidity strain. Even with low debt, poor operating cash generation forces reliance on financing or equity to cover capex and working capital, raising execution risk for capacity maintenance and limiting ability to capitalize on new long-term contracts.

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, hand sanitizers, laundry detergents, room fresheners, and denture products under the Dr. Gold and Aquawhite brands. It also provides contract manufacturing services for oral care products of other brands; and operates retail stores at airports. The company also exports its products. JHS Svendgaard Laboratories Limited was founded in 1996 and is based in New Delhi, India.

How the Company Makes Money

JHS primarily makes money by manufacturing oral care/personal care products and selling them to brand owners (including FMCG companies) under contract manufacturing and private-label agreements. Revenue is typically generated on a per-unit or per-batch basis based on customer purchase orders, with earnings driven by manufacturing volumes, plant utilization, and negotiated pricing that covers raw materials, conversion costs (labor, utilities, overhead), and a manufacturing margin. Additional income can come from supplying packaging/finished goods as part of an end-to-end production arrangement (where JHS procures inputs and delivers packed products) and from long-term supply relationships that provide recurring orders and better capacity planning. Specific details on individual customer concentration, named partnerships, pricing terms, or segment-level revenue breakdowns: null.

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

Financials are weak overall: revenue has declined materially over 2020–2025 and profitability is negative (net margin -21.47% in 2025; negative EBIT/EBITDA). Offsetting this, the balance sheet is relatively stable with a high equity ratio (85.83%) and very low leverage (debt-to-equity 0.037), but losses and negative free cash flow remain major risks.

Income Statement

The income statement shows a declining trajectory in revenue, with a significant drop from 2020 to 2025. Gross profit margin improved to 33.66% in 2025, indicating better cost management. However, the company has been unprofitable since 2021, with a negative net profit margin of -21.47% in 2025. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 85.83% in 2025, suggesting financial stability. The debt-to-equity ratio remains low at 0.037, which indicates low financial leverage. However, the return on equity is negative due to consistent losses, highlighting profitability issues.

Cash Flow

Cash flow analysis reveals a negative free cash flow in recent years, with a significant deterioration in 2025. The operating cash flow to net income ratio indicates challenges in converting revenue into cash, with a negative ratio in 2025. Despite positive financing cash flow, the company struggles with liquidity due to poor operating performance.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	935.64M	919.97M	698.06M	840.82M	854.91M	1.00B
Gross Profit	329.55M	309.55M	203.55M	165.45M	201.68M	264.03M
EBITDA	-15.86M	-39.92M	33.78M	-163.82M	85.45M	94.57M
Net Income	-79.38M	-197.44M	-40.58M	-175.17M	-40.52M	11.98M
Balance Sheet
Total Assets	2.07B	2.01B	1.97B	2.28B	2.22B	2.28B
Cash, Cash Equivalents and Short-Term Investments	200.11M	200.16M	94.56M	386.51M	80.19M	230.38M
Total Debt	105.87M	64.58M	51.29M	155.09M	61.82M	70.11M
Total Liabilities	332.52M	284.41M	271.70M	543.87M	269.46M	299.97M
Stockholders Equity	1.74B	1.73B	1.70B	1.74B	1.86B	1.89B
Cash Flow
Free Cash Flow	-29.85M	-157.11M	-401.17M	89.43M	-158.75M	36.96M
Operating Cash Flow	-29.85M	-51.78M	-85.84M	232.86M	-91.36M	120.29M
Investing Cash Flow	92.77M	-220.18M	-217.34M	96.77M	-46.97M	-22.25M
Financing Cash Flow	38.02M	232.97M	21.74M	-9.00M	-16.72M	103.09M

JHS Svendgaard Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Neutral. The current price of 9.34 is below the 20-day moving average (MA) of 9.72, below the 50-day MA of 10.10, and below the 200-day MA of 11.50, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 43.14 is Neutral, neither overbought nor oversold. The STOCH value of 27.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GROBTEA	70 Outperform	₹1.05B	4.09	―	0.30%	-20.04%	-104.83%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
JHS	51 Neutral	₹768.72M	27.28	―	―	16.77%	34.47%
NAGREEKEXP	51 Neutral	₹802.17M	31.72	―	―	-27.67%	-61.81%
PRITI	49 Neutral	₹494.34M	106.63	―	―	―	―

JHS Svendgaard Laboratories Limited Corporate Events

JHS Svendgaard Grants 250,000 Stock Options Under 2025 ESOP

JHS Svendgaard Laboratories Limited’s Nomination and Remuneration Committee has approved the grant of 250,000 employee stock options under its 2025 Employee Stock Option Scheme, each option convertible into one equity share of face value Rs. 10 at an exercise price set at par. The options, issued via fresh allotment and compliant with SEBI’s SBEB & SE Regulations, 2021, will vest over one to five years and can be exercised within five years of vesting, aligning employee incentives with long-term shareholder value and potentially modestly diluting equity upon full exercise.

The scheme’s pricing formula links the exercise price to market levels while ensuring it does not fall below face value, with the committee empowered to allow discounts within this floor. By structuring vesting and exercise windows over multiple years and targeting eligible employees based on predefined criteria, the company aims to strengthen retention, reward performance, and reinforce management commitment as it competes in its sector and navigates broader market conditions.

JHS Svendgaard Completes Rs 3.75 Crore Preferential Allotment to Coeus Global Opportunities Fund

JHS Svendgaard Laboratories Limited has approved the conversion of 18,01,801 fully convertible warrants into an equal number of equity shares of face value Rs 10 each at an issue price of Rs 27.75 per share, following receipt of the remaining 75% of the warrant price aggregating to about Rs 3.75 crore from Coeus Global Opportunities Fund, a non-promoter group investor. This preferential allotment on a private placement basis increases the company’s paid-up equity share capital to Rs 87.41 crore, with the newly issued shares ranking pari passu with existing equity, effectively completing the warrant conversion program disclosed earlier and marginally diluting existing shareholders while strengthening the company’s equity base.

Exchange Seeks Clarification from JHS Svendgaard on September 2025 Quarterly Results

The stock exchange has sought clarification from JHS Svendgaard Laboratories Limited regarding its financial results for the quarter ended 30 September 2025 under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements, 2015. The company’s response is still pending, leaving investors and other stakeholders awaiting further information on the queried aspects of its quarterly disclosures.